Native high density lipoproteins (HDL) interfere with platelet activation induced by oxidized low density lipoproteins (OxLDL)

International Journal of Molecular Sciences

Volumn 14, Issue 5, 2013, Pages 10107-10121

  Badrnya, Sigrun ^a   Assinger, Alice ^a,b   Volf, Ivo ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CD40 ligand; High density lipoproteins; Inflammation; Oxidized low density lipoproteins; Platelets; Reactive oxygen species

Indexed keywords

CD40 LIGAND; HIGH DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; REACTIVE OXYGEN METABOLITE; LOW DENSITY LIPOPROTEIN;

ARTICLE; BINDING COMPETITION; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUTROPHIL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; CELL ADHESION; CYTOLOGY; IMMUNOLOGY; INFLAMMATION;

BLOOD PLATELETS; CD40 LIGAND; CELL ADHESION; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; NEUTROPHILS; P-SELECTIN; PLATELET ACTIVATION; REACTIVE OXYGEN SPECIES;

EID: 84877830952     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140510107     Document Type: Article

References (48)

1. Stocker, R.; Keaney, J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004, 84, 1381-1478.
2. Yla Herttuala, S. Is oxidized low-density lipoprotein present in vivo? Curr. Opin. Lipidol. 1998, 9, 337-344.
3. Lievens, D.; von Hundelshausen, P. Platelets in atherosclerosis. Thromb. Haemost. 2011, 106, 827-838.
4. Gordon, T.; Castelli, W.P.; Hjortland, M.C.; Kannel, W.B.; Dawber, T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 1977, 62, 707-714.
5. Castelli, W.P.; Garrison, R.J.; Wilson, P.W.; Abbott, R.D.; Kalousdian, S.; Kannel, W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J. Am. Med. Assoc. 1986, 256, 2835-2838.
6. Toikka, J.O.; Ahotupa, M.; Viikari, J.S.; Niinikoski, H.; Taskinen, M.; Irjala, K.; Hartiala, J.J.; Raitakari, O.T. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis 1999, 147, 133-138.
7. Fielding, C.J.; Fielding, P.E. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 1995, 36, 211-228.
8. Mineo, C.; Shaul, P.W. Modulation of endothelial NO production by high-density lipoprotein. Cold Spring Harbor Symp. Quant. Biol. 2002, 67, 459-469.
9. Nofer, J.R.; Kehrel, B.; Fobker, M.; Levkau, B.; Assmann, G.; von Eckardstein, A. HDL and arteriosclerosis: Beyond reverse cholesterol transport. Atherosclerosis 2002, 161, 1-16.
10. Galle, J.; Ochslen, M.; Schollmeyer, P.; Wanner, C. Oxidized lipoproteins inhibit endothelium-dependent vasodilation. Effects of pressure and high-density lipoprotein. Hypertension 1994, 23, 556-564.
11. Kopprasch, S.; Pietzsch, J.; Graessler, J. The protective effects of HDL and its constituents against neutrophil respiratory burst activation by hypochlorite-oxidized LDL. Mol. Cell. Biochem. 2004, 258, 121-127.
12. Navab, M.; Imes, S.S.; Hama, S.Y.; Hough, G.P.; Ross, L.A.; Bork, R.W.; Valente, A.J.; Berliner, J.A.; Drinkwater, D.C.; Laks, H. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 1991, 88, 2039-2046.
13. Mertens, A.; Holvoet, P. Oxidized LDL and HDL: Antagonists in atherothrombosis. FASEB J. 2001, 15, 2073-2084.
14. Takahashi, Y.; Chiba, H.; Matsuno, K.; Akita, H.; Hui, S.P.; Nagasaka, H.; Nakamura, H.; Kobayashi, K.; Tandon, N.N.; Jamieson, G.A. Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins. Biochem. Biophys. Res. Commun. 1996, 222, 453-459.
15. Mehta, J.L.; Chen, L.Y. Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. J. Lab. Clin. Med. 1996, 127, 287-295.
16. Volf, I.; Bielek, E.; Moeslinger, T.; Koller, F.; Koller, E. Modification of protein moiety of human low density lipoprotein by hypochlorite generates strong platelet agonist. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 2011-2018.
17. Daugherty, A.; Dunn, J.L.; Rateri, D.L.; Heinecke, J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 1994, 94, 437-444.
18. Volf, I.; Roth, A.; Cooper, J.; Moeslinger, T.; Koller, E. Hypochlorite modified LDL are a stronger agonist for platelets than copper oxidized LDL. FEBS Lett. 2000, 483, 155-159.
19. Nergiz-Unal, R.; Lamers, M.M.; van Kruchten, R.; Luiken, J.J.; Cosemans, J.M.; Glatz, J.F.; Kuijpers, M.J.; Heemskerk, J.W. Signaling role of CD36 in platelet activation and thrombus formation on immobilized thrombospondin or oxidized low-density lipoprotein. J. Thromb. Haemost. 2011, 9, 1835-1846.
20. Krotz, F.; Sohn, H.Y.; Pohl, U. Reactive oxygen species: Players in the platelet game. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1988-1996.
21. Nofer, J.R.; Brodde, M.F.; Kehrel, B.E. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin. Exp. Pharmacol. Physiol. 2010, 37, 726-735.
22. Cettour-Rose, P.; Nguyen, T.X.; Serrander, L.; Kaufmann, M.T.; Dayer, J.M.; Burger, D.; Roux-Lombard, P. T cell contact-mediated activation of respiratory burst in human polymorphonuclear leukocytes is inhibited by high-density lipoproteins and involves CD18. J. Leukoc. Biol. 2005, 77, 52-58.
23. Pignatelli, P.; Sanguigni, V.; Lenti, L.; Ferro, D.; Finocchi, A.; Rossi, P.; Violi, F. gp91phox-dependent expression of platelet CD40 ligand. Circulation 2004, 110, 1326-1329.
24. Rizvi, M.; Pathak, D.; Freedman, J.E.; Chakrabarti, S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol. Med. 2008, 14, 530-538.
25. Andre, P.; Nannizzi-Alaimo, L.; Prasad, S.K.; Phillips, D.R. Platelet-derived CD40L: The switch-hitting player of cardiovascular disease. Circulation 2002, 106, 896-899.
26. Totani, L.; Evangelista, V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 2357-2361.
27. De Groot, P.G.; Urbanus, R.T.; Roest, M. Platelet interaction with the vessel wall. Handb. Exp. Pharmacol. 2012, 210, 87-110.
28. Michelson, A.D.; Barnard, M.R.; Krueger, L.A.; Valeri, C.R.; Furman, M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001, 104, 1533-1537.
29. Badrnya, S.; Butler, L.M.; Soderberg-Naucler, C.; Volf, I.; Assinger, A. Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein. Thromb. Haemost. 2012, 108, 719-729.
30. Soehnlein, O. Multiple roles for neutrophils in atherosclerosis. Circ. Res. 2012, 110, 875-888.
31. Naruko, T.; Ueda, M.; Haze, K.; van der Wal, A.C.; van der Loos, C.M.; Itoh, A.; Komatsu, R.; Ikura, Y.; Ogami, M.; Shimada, Y.; et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002, 106, 2894-2900.
32. Maugeri, N.; Rovere-Querini, P.; Evangelista, V.; Godino, C.; Demetrio, M.; Baldini, M.; Figini, F.; Coppi, G.; Slavich, M.; Camera, M.; et al. An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. PLoS One 2012, 7, e39484.
33. Murphy, A.J.; Woollard, K.J.; Suhartoyo, A.; Stirzaker, R.A.; Shaw, J.; Sviridov, D.; Chin-Dusting, J.P. Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1333-1341.
34. Faraday, N.; Scharpf, R.B.; Dodd-o, J.M.; Martinez, E.A.; Rosenfeld, B.A.; Dorman, T. Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand 1 with P-selectin. Anesthesiology 2001, 94, 145-151.
35. Weyrich, A.S.; Elstad, M.R.; McEver, R.P.; McIntyre, T.M.; Moore, K.L.; Morrissey, J.H.; Prescott, S.M.; Zimmerman, G.A. Activated platelets signal chemokine synthesis by human monocytes. J. Clin. Invest. 1996, 97, 1525-1534.
36. Nagata, K.; Tsuji, T.; Todoroki, N.; Katagiri, Y.; Tanoue, K.; Yamazaki, H.; Hanai, N.; Irimura, T. Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62). J. Immunol. 1993, 151, 3267-3273.
37. Korporaal, S.J.; van Eck, M.; Adelmeijer, J.; Ijsseldijk, M.; Out, R.; Lisman, T.; Lenting, P.J.; van Berkel, T.J.; Akkerman, J.W. Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 2476-2483.
38. Chen, R.; Chen, X.; Salomon, R.G.; McIntyre, T.M. Platelet activation by low concentrations of intact oxidized LDL particles involves the PAF receptor. Arterioscler. Thromb. Vasc. Biol. 2008, 29, 363-371.
39. Assinger, A.; Koller, F.; Schmid, W.; Zellner, M.; Koller, E.; Volf, I. Hypochlorite-oxidized LDL induces intraplatelet ROS formation and surface exposure of CD40L-A prominent role of CD36. Atherosclerosis 2010, 213, 129-134.
40. Calvo, D.; Gomez Coronado, D.; Suarez, Y.; Lasuncion, M.A.; Vega, M.A. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J. Lipid Res. 1998, 39, 777-788.
41. Volf, I.; Moeslinger, T.; Cooper, J.; Schmid, W.; Koller, E. Human platelets exclusively bind oxidized LDL showing no specificity for acetylated LDL. FEBS Lett. 1999, 449, 141-145.
42. Chen, L.Y.; Mehta, J.L. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci. 1994, 55, 1815-1821.
43. Nofer, J.R.; Walter, M.; Kehrel, B.; Wierwille, S.; Tepel, M.; Seedorf, U.; Assmann, G. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 861-869.
44. Brodde, M.F.; Korporaal, S.J.; Herminghaus, G.; Fobker, M.; van Berkel, T.J.; Tietge, U.J.; Robenek, H.; van Eck, M.; Kehrel B.E.; Nofer, J.R. Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI: Role of negatively charged phospholipids. Atherosclerosis 2011, 215, 374-382.
45. Assinger, A.; Schmid, W.; Eder, S.; Schmid, D.; Koller, E.; Volf, I. Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett. 2008, 582, 778-784.
46. Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
47. Assinger, A.; Laky, M.; Schabbauer, G.; Hirschl, A.; Buchberger, E.; Binder, B.R.; Volf, I. Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2. J. Thromb. Haemost. 2011, 9, 799-809.
48. Shaw, J.A.; Bobik, A.; Murphy, A.; Kanellakis, P.; Blombery, P.; Mukhamedova, N.; Woollard, K.; Lyon, S.; Sviridov, D.; Dart, A.M. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 2008, 103, 1084-1091.